Suppr超能文献

同二聚体和异二聚体表皮生长因子受体酪氨酸激酶的差异性内吞途径赋予受体异二聚体信号传导优势。

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

作者信息

Lenferink A E, Pinkas-Kramarski R, van de Poll M L, van Vugt M J, Klapper L N, Tzahar E, Waterman H, Sela M, van Zoelen E J, Yarden Y

机构信息

Department of Cell Biology, University of Nijmegen, Nijmegen, The Netherlands.

出版信息

EMBO J. 1998 Jun 15;17(12):3385-97. doi: 10.1093/emboj/17.12.3385.

Abstract

Both homo- and hetero-dimers of ErbB receptor tyrosine kinases mediate signaling by a large group of epidermal growth factor (EGF)-like ligands. However, some ligands are more potent than others, although they bind to the same direct receptor. In addition, signaling by receptor heterodimers is superior to homodimers. We addressed the mechanism underlying these two features of signal tuning by using three ligands: EGF; transforming growth factor alpha (TGFalpha); and their chimera, denoted E4T, which act on cells singly expressing ErbB-1 as a weak, a strong, and a very strong agonist, respectively. Co-expression of ErbB-2, a developmentally important co-receptor whose expression is frequently elevated in human cancers, specifically potentiated EGF signaling to the level achieved by TGFalpha, an effect that was partially mimicked by ErbB-3. Analysis of the mechanism underlying this trans-potentiation implied that EGF-driven homodimers of ErbB-1 are destined for intracellular degradation, whereas the corresponding heterodimers with ErbB-2 or with ErbB-3, dissociate in the early endosome. As a consequence, in the presence of either co-receptor, ErbB-1 is recycled to the cell surface and its signaling is enhanced. This latter route is followed by TGFalpha-driven homodimers of ErbB-1, and also by E4T-bound receptors, whose signaling is further enhanced by repeated cycles of binding and dissociation from the receptors. We conclude that alternative endocytic routes of homo- and hetero-dimeric receptor complexes may contribute to tuning and diversification of signal transduction. In addition, the ability of ErbB-2 to shunt ligand-activated receptors to recycling may explain, in part, its oncogenic potential.

摘要

ErbB受体酪氨酸激酶的同二聚体和异二聚体均通过一大类表皮生长因子(EGF)样配体介导信号传导。然而,一些配体比其他配体更具效力,尽管它们与相同的直接受体结合。此外,受体异二聚体介导的信号传导优于同二聚体。我们使用三种配体来探究信号调节这两个特征背后的机制:EGF;转化生长因子α(TGFα);以及它们的嵌合体E4T,它们分别作为弱、强和非常强的激动剂作用于单独表达ErbB-1的细胞。ErbB-2是一种在发育中起重要作用的共受体,其表达在人类癌症中经常升高,它的共表达特异性地增强了EGF信号传导至TGFα所达到的水平,ErbB-3部分模拟了这种效应。对这种转增强作用背后机制的分析表明,EGF驱动的ErbB-1同二聚体注定要进行细胞内降解,而与ErbB-2或ErbB-3形成的相应异二聚体则在内体早期解离。因此,在存在任何一种共受体的情况下,ErbB-1被循环至细胞表面,其信号传导得以增强。TGFα驱动的ErbB-1同二聚体以及E4T结合的受体也遵循后一种途径,它们的信号传导通过与受体的反复结合和解离循环而进一步增强。我们得出结论,同二聚体和异二聚体受体复合物的不同内吞途径可能有助于信号转导的调节和多样化。此外,ErbB-2将配体激活的受体分流至循环的能力可能部分解释了其致癌潜力。

相似文献

3
Alternative intracellular routing of ErbB receptors may determine signaling potency.
J Biol Chem. 1998 May 29;273(22):13819-27. doi: 10.1074/jbc.273.22.13819.
5
Bivalence of EGF-like ligands drives the ErbB signaling network.
EMBO J. 1997 Aug 15;16(16):4938-50. doi: 10.1093/emboj/16.16.4938.
8
Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.
EMBO J. 2000 Sep 1;19(17):4632-43. doi: 10.1093/emboj/19.17.4632.
10
The ErbB/HER family of protein-tyrosine kinases and cancer.
Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20.

引用本文的文献

1
Purine-Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors.
Pharmaceuticals (Basel). 2025 Jul 17;18(7):1051. doi: 10.3390/ph18071051.
2
FGFR2 residence in primary cilia is necessary for epithelial cell signaling.
J Cell Biol. 2025 Jul 7;224(7). doi: 10.1083/jcb.202311030. Epub 2025 Apr 21.
4
Emerging importance of HER3 in tumorigenesis and cancer therapy.
Nat Rev Clin Oncol. 2025 May;22(5):348-370. doi: 10.1038/s41571-025-01008-y. Epub 2025 Mar 14.
7
SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer.
Br J Cancer. 2024 Nov;131(9):1437-1449. doi: 10.1038/s41416-024-02853-x. Epub 2024 Sep 23.
9
The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.
Front Physiol. 2024 Mar 27;15:1358850. doi: 10.3389/fphys.2024.1358850. eCollection 2024.
10
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology.
Trends Cancer. 2024 Apr;10(4):312-331. doi: 10.1016/j.trecan.2024.01.003. Epub 2024 Feb 13.

本文引用的文献

1
Engineering epidermal growth factor for enhanced mitogenic potency.
Nat Biotechnol. 1996 Dec;14(13):1696-9. doi: 10.1038/nbt1296-1696.
2
Alternative intracellular routing of ErbB receptors may determine signaling potency.
J Biol Chem. 1998 May 29;273(22):13819-27. doi: 10.1074/jbc.273.22.13819.
4
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands.
Biochim Biophys Acta. 1998 Feb 20;1377(1):M25-37. doi: 10.1016/s0304-419x(97)00032-2.
6
Bivalence of EGF-like ligands drives the ErbB signaling network.
EMBO J. 1997 Aug 15;16(16):4938-50. doi: 10.1093/emboj/16.16.4938.
8
Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis.
Neuron. 1997 Jun;18(6):847-55. doi: 10.1016/s0896-6273(00)80324-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验